Clinical parameters from cohort as compared to clinical trial
| . | UNC, median (range) . | Kruse-Jarres et al,14 median . |
|---|---|---|
| Total dose/24 h, U/kg | 200 (100-400) | 741 |
| Cumulative dose, U/kg | 512.5 (150-8625) | 2057 |
| Initial dose, U/kg | 100 (50-200) | 200 |
| First-dose FVIII recovery, % | 99.5 (<1-318) | 216 |
| Peak FVIII activity/24-h period, % | 136 (<1-391) | 308 |
| Dosing interval, h | 8 (4-24) | 10.2 |
| . | UNC, median (range) . | Kruse-Jarres et al,14 median . |
|---|---|---|
| Total dose/24 h, U/kg | 200 (100-400) | 741 |
| Cumulative dose, U/kg | 512.5 (150-8625) | 2057 |
| Initial dose, U/kg | 100 (50-200) | 200 |
| First-dose FVIII recovery, % | 99.5 (<1-318) | 216 |
| Peak FVIII activity/24-h period, % | 136 (<1-391) | 308 |
| Dosing interval, h | 8 (4-24) | 10.2 |
Comparison of select clinical and laboratory parameters between our cohort and the phase 2/3 trial that led to FDA approval of rpFVIII for use in AHA.